Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

被引:9
|
作者
Ren, Yifan [1 ]
Song, Jialong [1 ]
Li, Xinyi [1 ]
Luo, Na [1 ]
机构
[1] Nankai Univ, Sch Med, Dept Histol, Tianjin 300071, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer therapy; metastatic triple-negative breast cancer; anticancer drugs; immunotherapy; immune checkpoint blockade therapy; PD-1; PD-L1; clinical trails; CHECKPOINT BLOCKADE; ANTITUMOR IMMUNITY; 1ST-LINE TREATMENT; PLUS CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; T-CELLS; ATEZOLIZUMAB; PEMBROLIZUMAB; THERAPY;
D O I
10.3390/ijms23168878
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combination of PD-1/PD-L1 inhibitors with other therapies is a noteworthy treatment strategy. Immunotherapy in combination with chemotherapy or small-molecule inhibitors still faces many challenges. Additionally, there are some new immunotherapy targets in development. We aimed to further evaluate the effectiveness and usefulness of immunotherapy for treating mTNBC and to propose new immunotherapy strategies. This review explains the rationale and results of existing clinical trials evaluating PD-1/PD-L1 inhibitors alone or in combination for the treatment of mTNBC. For patients with aggressive tumors and poor health, PD-1/PD-L1 inhibitors, either alone or in combination with other modalities, have proven to be effective. However, more research is needed to explore more effective immunotherapy regimens that will lead to new breakthroughs in the treatment of mTNBC.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer
    Li, Jia-Xin
    Huang, Ju-Min
    Jiang, Ze-Bo
    Li, Run-Ze
    Sun, Ao
    Leung, Elaine Lai-Han
    Yan, Pei-Yu
    INTEGRATIVE CANCER THERAPIES, 2019, 18
  • [42] BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response
    Andrieu, Guillaume P.
    Shafran, Jordan S.
    Smith, Charlotte L.
    Belkina, Anna C.
    Casey, Allison N.
    Jafari, Naser
    Denis, Gerald V.
    CANCER LETTERS, 2019, 465 : 45 - 58
  • [43] Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
    Li, Chia-Wei
    Lim, Seung-Oe
    Chung, Ezra M.
    Kim, Yong-Soo
    Park, Andrew H.
    Yao, Jun
    Cha, Jong-Ho
    Xia, Weiya
    Chan, Li-Chuan
    Kim, Taewan
    Chang, Shih-Shin
    Lee, Heng-Huan
    Chou, Chao-Kai
    Liu, Yen-Liang
    Yeh, Hsin-Chih
    Perillo, Evan P.
    Dunn, Andrew K.
    Kuo, Chu-Wei
    Khoo, Kay-Hooi
    Hsu, Jennifer L.
    Wu, Yun
    Hsu, Jung-Mao
    Yamaguchi, Hirohito
    Huang, Tzu-Hsuan
    Sahin, Aysegul A.
    Hortobagyi, Gabriel N.
    Yoo, Stephen S.
    Hung, Mien-Chie
    CANCER CELL, 2018, 33 (02) : 187 - +
  • [44] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
    Alsaab, Hashem O.
    Sau, Samaresh
    Alzhrani, Rami
    Tatiparti, Katyayani
    Bhise, Ketki
    Kashaw, Sushil K.
    Iyer, Arun K.
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [45] PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging-A Literature Review
    Planes-Laine, Gabrielle
    Rochigneux, Philippe
    Bertucci, Francois
    Chretien, Anne-Sophie
    Viens, Patrice
    Sabatier, Renaud
    Goncalves, Anthony
    CANCERS, 2019, 11 (07)
  • [46] A multitier virtual screening of antagonists targeting PD-1/PD-L1 interface for the management of triple-negative breast cancer
    Krishnamoorthy, HemaNandini Rajendran
    Karuppasamy, Ramanathan
    MEDICAL ONCOLOGY, 2023, 40 (11)
  • [47] The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
    Michael T. Barrett
    Elizabeth Lenkiewicz
    Smriti Malasi
    Anamika Basu
    Jennifer Holmes Yearley
    Lakshmanan Annamalai
    Ann E. McCullough
    Heidi E. Kosiorek
    Pooja Narang
    Melissa A. Wilson Sayres
    Meixuan Chen
    Karen S. Anderson
    Barbara A. Pockaj
    Breast Cancer Research, 20
  • [48] A multitier virtual screening of antagonists targeting PD-1/PD-L1 interface for the management of triple-negative breast cancer
    HemaNandini Rajendran Krishnamoorthy
    Ramanathan Karuppasamy
    Medical Oncology, 40
  • [49] PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
    Zhang, Jian-ye
    Yan, Yan-yan
    Li, Jia-jun
    Adhikari, Rameshwar
    Fu, Li-wu
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [50] The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
    Barrett, Michael T.
    Lenkiewicz, Elizabeth
    Malasi, Smriti
    Basu, Anamika
    Yearley, Jennifer Holmes
    Annamalai, Lakshmanan
    McCullough, Ann E.
    Kosiorek, Heidi E.
    Narang, Pooja
    Sayres, Melissa A. Wilson
    Chen, Meixuan
    Anderson, Karen S.
    Pockaj, Barbara A.
    BREAST CANCER RESEARCH, 2018, 20